China's latest proposed rules governing the overseas transfer of personal data may allow pharma, biotech and digital health companies to avoid regulatory security reviews and formal standard contracts, as well as personal information protection certification, but key definitions of “important data” and “negative list” items remain to be clarified.

The future fate of Jiangsu Hengrui’s new drug discovery and development subsidiary may provide some tips on what’s ahead for the Chinese biopharma sector.

Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.